Skip to main contentSkip to navigationSkip to search
HNSA (, %) SEK
Hansa Biopharma logotype

Hansa Medical announces successful completion of a Phase II clinical trial of IdeS in sensitized kidney patients

Regulatory information
Hansa Medical AB (Nasdaq Stockholm: HMED), a biopharmaceutical company focusing on novel immunomodulatory enzymes, announces The second Swedish open label Phase II IdeS-study conducted at Uppsala University Hospital and Karolinska University Hospital in Huddinge is now complete with all IdeS treated patients transplanted.

Hansa Medical AB today announced completion of a Phase II study entitled “A Phase II Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of Intravenous Ascending Doses of IdeS in Kidney Transplantation” in which 10 sensitized kidney patients were given IdeS prior to transplantation. The primary and secondary objectives were met with IdeS in the study.

Dr. Steven Glazer, Chief Medical Officer at Hansa Medical said, “We are encouraged by these results. These data further support our belief that our novel immunomodulatory enzyme holds significant therapeutic value for sensitized patients in need of lifesaving transplantation. We plan to move forward with continued recruitment of patients to our ongoing multi-center study with IdeS in highly sensitized kidney transplantation patients, allowing us to accumulate additional data and further evidence of the value of IdeS and our clinical program.” 

Data generated from this trial have been submitted for peer review in a scientific journal.

This information is information that Hansa Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 09:45am CET on December 21, 2016.